Patients with mutations in EPAS1, the gene encoding HIF2α, have been reported to develop polycythemia and neuroendocrine tumors in dozens of patients (Därr et al., 2016; Taieb et al., 2016; Tarade et al., 2018). Here, EPAS1 is linked to neuroendocrine neoplasm.